Drug Profile
CLR 457
Alternative Names: CLR-457Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Novartis Pharmaceuticals Corporation
- Class Antineoplastics
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 14 Jan 2016 Discontinued - Phase-I/II for Solid tumours (Late-stage disease) in USA, Canada, France, Japan, Singapore and Spain (PO)
- 01 Aug 2014 Phase-I/II clinical trials in Solid tumours (Late-stage disease) in USA & Canada (PO)
- 01 Jul 2014 Novartis Pharmaceuticals plans a phase I/II trial for Solid tumours in the US, Austria, Canada, France, Israel, Italy, Singapore and Spain (NCT02189174)